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Abstract
Background: Cervical intraepithelial neoplasia (CIN) is the premalignant condition of cervical cancer. Whereas not all
high grade CIN lesions progress to cervical cancer, the natural history and risk of progression of individual lesions remain
unpredictable. Therefore, high-grade CIN is currently treated by surgical excision: large loop excision of the transformation
zone (LLETZ). This procedure has potential complications, such as acute haemorrhage, prolonged bleeding, infection and
preterm birth in subsequent pregnancies. These complications could be prevented by development of a non-invasive
treatment modality, such as topical imiquimod treatment.
The primary study objective is to investigate the efficacy of topical imiquimod 5 % cream for the treatment of high-grade
CIN and to develop a biomarker profile to predict clinical response to imiquimod treatment. Secondary study objectives
are to assess treatment side-effects, disease recurrence and quality of life during and after different treatment modalities.
Methods/design: The study design is a randomized controlled trial. One hundred forty women with a histological
diagnosis of high-grade CIN (CIN 2–3) will be randomized into two arms: imiquimod treatment during 16 weeks
(experimental arm) or immediate LLETZ (standard care arm). Treatment efficacy will be evaluated by colposcopy with
diagnostic biopsies at 20 weeks for the experimental arm. Successful imiquimod treatment is defined as regression to CIN
1 or less, successful LLETZ treatment is defined as PAP 1 after 6 months. Disease recurrence will be evaluated by cytology
at 6, 12 and 24 months after treatment. Side-effects will be evaluated using a standardized report form. Quality of life will
be evaluated using validated questionnaires at baseline, 20 weeks and 1 year after treatment. Biomarkers, reflecting both
host and viral factors in the pathophysiology of CIN, will be tested at baseline with the aim of developing a predictive
biomarker profile for the clinical response to imiquimod treatment.
Discussion: Treatment of high-grade CIN lesions with imiquimod in a selected patient population may diminish
complications as a result of surgical intervention. More knowledge on treatment efficacy, side effects and long-term
recurrence rates after treatment is necessary.
Trial registration: EU Clinical Trials Register EU-CTR2013-001260-34. Registered 18 March 2013.
Medical Ethical Committee approval number: NL44336.068.13 (Medical Ethical Committee Maastricht University Hospital,
University of Maastricht).
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Background
Cervical intraepithelial neoplasia (CIN) is the prema-
lignant condition of cervical cancer and is caused by
cervical human papillomavirus (HPV) infection [1].
The natural history of individual CIN lesions is un-
predictable. Approximately 30 % of high-grade CIN
progresses to cervical cancer [2, 3]. On the contrary,
recent evidence suggests that spontaneous regression
occurs in approximately 20–40 % of high-grade le-
sions [4–7]. Current histopathological assessment is
unable to differentiate between lesions that will pro-
gress to cervical cancer and those that will regress
spontaneously. Therefore, all high-grade CIN lesions
are currently treated by surgical excision, consisting
of large loop excision of the transformation zone
(LLETZ). This treatment is associated with potential
complications. Short term complications include pain,
vaginal discharge and bleeding. The most serious late
complication is premature birth in subsequent preg-
nancy, probably due to cervical insufficiency [8–10].
Evidence shows a two fold increase in premature
birth between 32/34 and 37 weeks in patients who
were treated with LLETZ. Furthermore, cervical sur-
gery for CIN may be associated with subfertility. A
recent case–control study in 152 patients who under-
went cervical surgery showed a twofold increase in
prolonged time to conception (16.4 % vs 8.6 %) for
patients who underwent LLETZ [11]. Since cervical
dysplasia is most common in women of childbearing
age, these potential complications are of special inter-
est to the patient population and surgical intervention
should be avoided if possible. Therefore, an effective
non-invasive treatment modality is needed. A poten-
tial agent in non-invasive therapy is imiquimod
cream. Imiquimod is an immunomodulator with anti-
viral and anti-tumour effects. It is a toll-like receptor
7 agonist and induces up regulation of interferon and
activation of dendritic cells [12]. It is currently used
in treatment of basal cell carcinoma, actinic keratosis
and external genital warts in adults. As an off-label
drug, it has also been proven effective in the treat-
ment of HPV related vulvar intraepithelial neoplasia
(VIN) [13]. The use of imiquimod in CIN has been
studied by several authors [7, 14, 15]. Only one ran-
domized controlled trial was conducted, evaluating
the efficacy of imiquimod treatment in high-grade
CIN [7]. Grimm et al. included 59 patients, who were
randomized for treatment with imiquimod or placebo
during 16 weeks. The study results are promising:
both histologic regression and complete remission of
high-grade CIN was significantly more frequent in pa-
tients treated with imiquimod, compared to the
control arm (73 % vs 39 % and 47 % vs 14 % respect-
ively). However, side-effects seem common and long-
term outcomes are unknown.
Ideally, the response to imiquimod treatment of an in-
dividual patient would be predictable. Previous studies
have shown that the natural behaviour of CIN lesions
can be partially predicted by biomarker models, consist-
ing of markers that reflect host, viral and cellular factors
[4, 16]. This study aims to develop a similar biomarker
prediction model for the individual response to imiqui-
mod treatment, in order to enable individualized treat-
ment of CIN lesions.
This study aims to confirm the short and long term
efficacy of imiquimod 5 % cream in the treatment of
high-grade CIN, as well as to evaluate clinical applic-
ability by assessment of side-effects and quality of life
during and after treatment. Additionally, it aims to
develop a biomarker prediction model for clinical re-
sponse to imiquimod treatment of high-grade CIN.
For this purpose, we designed a randomized con-
trolled trial with two arms, in which imiquimod treat-
ment is compared to standard treatment by LLETZ.
The trial was designed according to the CONSORT
guidelines.
Methods
Setting and study population
The study will be started at the outpatient clinic of
gynecologic oncology, Maastricht University Medical
Center, the Netherlands and is intended as a multi-
center trial in the future. Inclusion criteria are newly
diagnosed, histologically confirmed high-grade CIN le-
sions (CIN 2–3) and age above 18 years. Exclusion
criteria are previous histologically confirmed high-
grade CIN (CIN 2–3), concomitant vulvar and/or
vaginal intraepithelial neoplasia, previous cervical ma-
lignancy, current malignant disease, immunodeficiency
(including HIV/AIDS and immunodepressive medica-
tion), pregnancy or lactation and legal incapability.
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Study objectives and outcome measures
The primary study objectives and outcome measures
are:
1. Assessment of treatment efficacy of imiquimod
treatment for high-grade CIN, as compared to
LLETZ treatment. Successful treatment for the ex-
perimental (imiquimod) arm is defined as regression
to CIN 1 or less in diagnostic biopsies at 20 weeks
follow-up. Successful treatment for the LLETZ arm is
defined as normal cytology at 6 months follow-up.
Based upon earlier studies, we hypothesize that
50–75 % of patients in the experimental (imiquimod)
arm will show regression to CIN 1 or less.
These two different outcome measures (cytology in
the LLETZ arm and histology in the experimental
arm) were selected in order to optimize the
assessment of treatment efficacy, whilst limiting
overtreatment of patients (performing unnecessary
biopsies or LLETZ treatments). For the experimental
arm, it is assessed by colposcopy with diagnostic
biopsies and for the LLETZ arm it is assessed by
cytology. Regarding efficacy of LLETZ treatment,
the significance of resection margins of the LLETZ
specimen is controversial and is not advised in
guidelines as outcome measure of LLETZ efficacy.
Therefore, regular follow-up cytology at six months
was selected as outcome measure, as is also done in
clinical practice. Regarding imiquimod treatment,
histological assessment of treatment efficacy was
selected as outcome measure, in order to optimize
the assessment of potential residual disease. Biopsies
were chosen rather than a standard LLETZ procedure
to evaluate residual disease, to prevent
overtreatment.
2. Development of a biomarker model to predict
adequate response to imiquimod treatment.
Secondary study objectives and outcome measures are:
1. To determine the incidence and severity of side
effects of LLETZ and imiquimod therapy, scored by
the Common Terminology Criteria for Adverse
Events guidelines.
2. To estimate disease recurrence rates for both arms
at 6, 12 and 24 months follow-up, defined as
abnormal cervical cytology. The follow-up term
starts after treatment is finished.
3. To assess Quality of life (QoL) for both arms before,
during and after treatment (at 0 and 20 weeks and
after 1 year) by the following QoL questionnaires:
[1] Medical Outcomes Study 36-Item Short-Form
General Health Survey (RAND 36), to assess generic
health-related quality of life, [2] the European
Organization for Research and Treatment of Cancer
(EORTC) QLQ-C30, to assess cancer-specific
health-related quality of life, and [3] the European
Organization for Research and Treatment of Cancer
(EORTC) QLQ-CX24, to assess cervical cancer
specific quality of life, including sexual functioning.
Interventions
After informed consent is obtained, patients are equally
randomized into one of two arms:
1. Experimental arm. Patients in this arm are treated
by a 16-week regime of imiquimod 5 % cream.
2. Standard arm. Patients in this arm receive standard
treatment by LLETZ.
Follow-up visits are anchored to the start of the treat-
ment (either imiquimod or LLETZ). Cytological assess-
ment will be performed by two independent trained
cytology analysts, according to the Papanicolaou system.
In case of inconsistent results, a consensus will be
reached by discussion. The histopathological assessment
of cervical biopsies will be performed by two independ-
ent pathologists according to national guidelines, based
on the WHO guidelines. In case of inconsistent results,
a consensus will be reached by discussion. CIN diagnosis
will be based on evaluation of histological features con-
cerned with differentiation, maturation and stratification
of cells and nuclear abnormalities, in combination with
p16 staining. In CIN 1 there is good maturation with
minimal nuclear abnormalities and few mitotic figures.
Undifferentiated cells are confined to the deeper layers
(lower third) of the epithelium. Mitotic figures are
present, but not very numerous. Cytopathic changes due
to HPV infection may be observed in the full thickness
of the epithelium. CIN 2 is characterized by dysplastic
cellular changes mostly restricted to the lower half or
the lower two-thirds of the epithelium, with more
marked nuclear abnormalities than in CIN 1. Mitotic fig-
ures may be seen throughout the lower half of the epi-
thelium. In CIN 3, differentiation and stratification may
be totally absent or present only in the superficial quar-
ter of the epithelium with numerous mitotic figures.
Nuclear abnormalities extend throughout the thickness
of the epithelium. Many mitotic figures have abnormal
forms.
Patients in the experimental arm are treated with imi-
quimod 5 % cream during 16 weeks. Imiquimod 5 %
cream is administered in a vaginal applicator, containing
12,5 mg of imiquimod (one sachet). The cream is ad-
ministered three times per week. The cream is adminis-
tered by patients themselves at night, before going to
bed. A vaginal shower is performed in the morning in
order to remove cream remainders. In case of mild
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systemic drug-related side effects, patients are offered a
prescription for anti-inflammatory drugs (paracetamol
or NSAID). In case of more severe or persistent systemic
or severe local side effects (Common Terminology Cri-
teria for Adverse Events grade 2 or higher), the fre-
quency of imiquimod application is decreased to twice
per week, and subsequently to once per week if side ef-
fects persist. Imiquimod treatment is discontinued if side
effects are unacceptable to patients hereafter. Subjects
should use adequate contraception in order to prevent
pregnancy. Subjects should not have vaginal sexual
intercourse from the time of application of the imiqui-
mod cream until the vaginal shower the next morning.
A control colposcopy with diagnostic biopsies is per-
formed after 10 weeks to rule out disease progression.
Biopsies are performed at the initial high-grade CIN le-
sion site and at any other suspect site, with a minimum
of two. In case of progressive disease (defined as increase
in lesions size with stable disease grade, higher disease
grade or invasive disease), surgical excision is performed.
Treatment efficacy for the experimental arm is eval-
uated at 20 weeks follow-up, by colposcopy with diag-
nostic biopsies. Biopsies are performed by using a
cervical biopsy specimen forceps (Aesculap ER055R),
at the initial high-grade CIN lesion site and at any
other suspect site, with a minimum of two. In case of
persistent or progressive disease (> CIN 1), surgical
excision is performed.
Patients in the standard treatment arm undergo
LLETZ at short term (within 4 weeks after the diagno-
sis). Excision of the transformation zone and macro-
scopic lesions is performed by a monopolar loop
electrode, under local anaesthesia. A summary of study
interventions can be found in Fig. 1.
The imiquimod treatment period was set at
20 weeks, in order to realize adequate treatment effi-
cacy of imiquimod, while minimizing the risk of pro-
gression of cervical dysplasia to invasive disease.
Progression of CIN into cervical cancer is considered
to be a slow process. The annual risk of progression
of CIN 3 to invasive cervical cancer is estimated to
be less than 1 % [17]. We identified ten studies in
which patients with high-grade CIN underwent watch-
ful waiting for a set period of time [4, 6, 7, 18–24]. A total
of 637 patients were included either as a control
group, receiving no treatment during 6 weeks to
15 months, or followed during the period between
diagnosis and LLETZ. Three cases of invasive disease
were identified: all occurred in the same study after
16 weeks of observation. The possibility of invasive
disease already present at the initial colposcopy (due
to biopsy error) cannot be excluded. Based on these
Fig. 1 Summary of study interventions
Koeneman et al. BMC Cancer  (2016) 16:132 Page 4 of 7
results, we set the maximum treatment period at
20 weeks and we included an additional control col-
poscopy with diagnostic biopsies after 10 weeks.
When no disease progression is detected during this col-
poscopy, the imiquimod treatment can be continued until
the 20 weeks colposcopy.
Sample size calculation
The sample size calculation was based on a regression
rate of 73 % at 20 weeks follow-up after immunotherapy
and a 95 % treatment efficacy of LLETZ. Using 80 %
power and alpha = 5 %, the estimated sample size re-
quired is 42 women in both arms. Allowing for a with-
drawal rate of approximately 20 %, 53 women will have
to be recruited in each arm. Sample size calculations for
the secondary outcome measures indicated that roughly
70 patients per treatment arm would be necessary. Al-
though the sample size calculation should be based on
the primary outcome measure, we decided to recruit a
total of 140 patients (70 per arm).
Randomization
Randomization is performed by the principal investiga-
tor to prevent selection and allocation bias, by use of a
computerized randomization tool. Sampling is stratified
according to the following age categories: 18–24, 25–39,
and 40 years and older. Sampling will be stratified ac-
cording to study centre.
Data collection
Coded data are stored both on paper and in an elec-
tronic database. Collected data are stored in a digital
case report form (CRF). Raw data is available only to
the principal and coordinating investigator. The fol-
lowing data are recorded:
Baseline
– Patients characteristics: age, ethnical background,
education, medical history, smoking, sexual
behaviour.
– HPV genotyping.
– Histological biomarkers on biopsies of patients in
the experimental arm: markers of
lymphoproliferative response: CD4, CD8, CD25,
CD138, fox p3; cell cycle markers: p16, Rb, p53,
Ki67, CK 13, CK 14, IMP3.
– Quality of life.
6 weeks follow-up
– Adverse effects of imiquimod treatment: patient
reported side effects and side effects noticed at
clinical investigation.
– Adverse effects of LLETZ treatment: patient
reported side effects, using a standardized report
form.
10 weeks follow-up
– Treatment compliance: amount of applied doses of
imiquimod, as documented by the study subject on
a dose calendar.
– Histological presence and grading of CIN for the
experimental arm.
– Adverse effects of imiquimod treatment: patients
reported side effects and side effects noticed at
clinical investigation.
14 weeks follow-up
– Adverse effects of imiquimod treatment: patients
reported side effects and side effects noticed at
clinical investigation.
20 weeks follow-up
– Treatment compliance: amount of applied doses of
imiquimod, as documented by the study subject on
a dose calendar.
– Histological presence and grading of CIN for the
experimental arm.
– Adverse effects of imiquimod treatment: patients
reported side effects and side effects noticed at
clinical investigation.
– Quality of life for all patients.
6, 12, 24 months follow-up
– Cervical cytology outcomes for all patients,
including HPV genotyping.
– Quality of life for all patients at 12 months follow-up
Statistical methods
Logistic regression analysis will be used to evaluate treat-
ment efficacy of imiquimod treatment, compared to
LLETZ treatment. Covariates in this analysis are age at
diagnosis, CIN grade, smoking and HPV-subtype. Ana-
lysis will be based on intention-to-treat protocol. A bio-
marker prediction model for adequate response to
imiquimod treatment will be developed by backward lo-
gistic regression analysis of biomarkers based on likeli-
hood ration tests. The prevalence and severity of side
effects of imiquimod and LLETZ treatment will be pre-
sented as proportions and means with 95 % confidence
intervals. Differences in the rates of overall side-effects
and severe side-effects between the imiquimod and
LLETZ arms will be tested with a chi-square test.
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Disease recurrence rates after 6, 12 and 24 months will
be evaluated in successfully treated patients by use of
multiple logistic regression analysis, after adjustment for
age at diagnosis, CIN grade, smoking, sexual behaviour
and HPV subtype. Repeated-measures analysis of vari-
ance will be used to test for between-group differences
over time in Quality of Life scores. Analysis of covari-
ance will be used to compare group scores on these out-
comes at 20 weeks and at 12 months, with adjustment
for baseline scores.
Withdrawal of individual subjects and replacement
Subjects can leave the study at any time for any reason,
without consequences. The investigator can decide to
withdraw a subject from the study for medical reasons.
Withdrawn individuals are not replaced by a new volun-
teer. Patients who withdraw from the study are offered
the standard treatment of CIN, being a LLETZ proced-
ure with standard follow up.
Ethical considerations and dissemination
The study was approved off by the Medical Ethical
Committee of Maastricht University Hospital, University
of Maastricht. The study will be performed according to
the standards outlined in the Declaration of Helsinki.
Ethics committee approval has been completed. Moni-
toring of the study is performed by a Data and Safety
Monitoring Board, appointed by the Clinical Trial
Center Maastricht. Adverse events are recorded and
reported according to local protocol. Study results will
be offered for publication in an international medical
journal. Study results will be communicated to trial
participants by mail, if agreed upon by the participant.
Substantial amendment
The current study protocol includes a substantial
amendment to the original study protocol, which con-
sisted of three study arms: imiquimod treatment arm,
LLETZ treatment arm and an observational arm. The
purpose of the observational arm was to assess spon-
taneous regression of high-grade CIN and to develop
a prognostic biomarker panel to predict spontaneous
regression of high-grade CIN. Patients in the observa-
tional arm underwent no treatment for a period of
maximum 20 weeks. Histological assessment of disease
development was performed after 10 and 20 weeks by
colposcopy with diagnostic biopsies. Inclusion of
patients into the study was hampered by the observa-
tional arm: patients declined the study because they
wished to be treated, rather than undergo observational
management. The observational arm was removed from
the study.
Discussion
The development of a non-invasive treatment modality for
high-grade CIN lesions may diminish complications as a
result of surgical intervention. An earlier study indicates
that imiquimod induces disease regression in 73 % [7, 13].
Thus, imiquimod treatment may prevent surgical treat-
ment in the majority of patients. The current study aims to
test the treatment efficacy hypothesis as well as long term
disease recurrence after treatment and clinical applicability
of imiquimod treatment, defined as side effects and quality
of life during and after treatment. Furthermore, it aims to
develop a prediction model for clinical response to imiqui-
mod treatment, based on histological biomarkers.
Trial status
First approved by the Medical Ethical Committee Maastricht
University 1Hospital, University of Maastricht, on 21 May
2014. Recruitment started in December 2014. Protocol
version 5.0.
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